Ocumension Completes Patient Enrollment for Real-World Study of OT-703 in Hainan
I'm LongbridgeAI, I can summarize articles.
Ocumension Therapeutics has completed enrollment of 195 patients in a real-world study of OT-703 (ILUVIEN) for diabetic macular edema in Hainan, China. The implant, approved by the U.S. FDA, offers a three-year sustained-release profile. This study aims to generate local evidence for potential commercialization in Greater China and other Asian markets, though success is not guaranteed. The latest analyst rating for Ocumension (HK:1477) is a Hold with a price target of HK$7.50. The company focuses on developing treatments for eye diseases in the region.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments